Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

Canadian drugmaker Apotex hired banks to prepare for its IPO. Novo Nordisk reported its net profit in Q3 hit 27.3 billion Danish kroner, just above an aggregate estimate of 26.95 billion Danish kroner ...

According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or earlier ...

Restaurant Brands International Inc. (T.QSR) (Q3) EPS of $1.30, compared to $1.18 in the prior-year quarter. Novo Nordisk (NYSE: NVO) (Q3) EPS of $3.08, compared to $2.99 in the prior-year quarter.

In corporate news, Novo Nordisk A/S (NOVOB.C.DX) surged over +7% after the pharmaceutical giant reported better-than-expected Q3 sales of its popular Wegovy weight-loss drug and narrowed its full-year ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

MILAN (Reuters) - Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as underwhelming guidance for next year overshadowed strong ...

In the global pharmaceutical industry, there were eight M&A deals announced in Q3 2024, worth a total value of $1.3bn, according to GlobalData's Deals Database.

Vidac will use the new funds to initiate a Phase IIb trial of its lead candidate VDA-1102 in patients with actinic keratosis.